Why Did SoFi Stock Drop?
Fintech platform SoFi (NASDAQ:SOFI) has stumbled in recent days, selling…
Sell
45
BOLT Quote, Financials, Valuation and Earnings
Last price:
$5.31
Seasonality move
:
-11.17%
Day range:
$5.11 - $5.45
52-week range:
$4.41 - $12.60
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
11.50x
P/B ratio:
0.32x
Volume:
5.9K
Avg. volume:
31.6K
1-year change:
-51.87%
Market cap:
$10.4M
Revenue:
$7.7M
EPS (TTM):
-$16.80
Analysts' Opinion
-
Consensus RatingBolt Biotherapeutics, Inc. has received a consensus rating of Hold. The company's average rating is a Hold based on 2 Buy ratings, 3 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $22.00, Bolt Biotherapeutics, Inc. has an estimated upside of 305.9% from its current price of $5.42.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $1.00 representing 100% downside risk from its current price of $5.42.
Fair Value
-
According to the consensus of 5 analysts, Bolt Biotherapeutics, Inc. has 305.9% upside to fair value with a price target of $22.00 per share.
BOLT vs. S&P 500
-
Over the past 5 trading days, Bolt Biotherapeutics, Inc. has overperformed the S&P 500 by 6.57% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Bolt Biotherapeutics, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Bolt Biotherapeutics, Inc. has grown year-over-year revenues for 2 quarters straight. In the most recent quarter Bolt Biotherapeutics, Inc. reported revenues of $2.2M.
Earnings Growth
-
Bolt Biotherapeutics, Inc. earnings have been falling on a year-over-year basis for 4 quarters in a row. In the most recent quarter Bolt Biotherapeutics, Inc. reported earnings per share of -$3.72.
Enterprise value:
1.3M
EV / Invested capital:
0.02x
Price / LTM sales:
11.50x
EV / EBIT:
--
EV / Revenue:
0.25x
PEG ratio (5yr expected):
0.00x
EV / Free cash flow:
-0.03x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$3.7M
Return On Assets:
-49.02%
Net Income Margin (TTM):
-821.58%
Return On Equity:
-86.41%
Return On Invested Capital:
-58.81%
Operating Margin:
-355.14%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | $7.2M | $9.8M | $5.2M | $1.1M | $2.2M | |
| Gross Profit | $3.2M | $7.9M | $3.7M | $701K | $1.9M | |
| Operating Income | -$77.5M | -$72.3M | -$44.7M | -$16.4M | -$7.7M | |
| EBITDA | -$73.5M | -$70.5M | -$43.2M | -$16M | -$7.4M | |
| Diluted EPS | -$1.89 | -$1.71 | -$16.80 | -$0.40 | -$3.72 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $222.5M | $174.8M | $125.5M | $57.1M | $35.6M | |
| Total Assets | $333.6M | $245.5M | $175.4M | $109.3M | $65.1M | |
| Current Liabilities | $23.7M | $24.2M | $18.8M | $18.1M | $10M | |
| Total Liabilities | $58.6M | $57.1M | $47.1M | $37.3M | $33M | |
| Total Equity | $274.9M | $188.4M | $128.3M | $72M | $32.1M | |
| Total Debt | $22.5M | $20.9M | $18.2M | $15.4M | $20.9M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$73.2M | -$61.1M | -$47.1M | -$14M | -$9.7M | |
| Cash From Investing | $71.7M | $61.2M | $55.5M | $17.1M | $17.9M | |
| Cash From Financing | $291K | $185K | $43K | -- | -- | |
| Free Cash Flow | -$73.6M | -$61.2M | -$47.2M | -$14M | -$9.8M | |
BOLT
Sector
Market Cap
$10.4M
$28.5M
Price % of 52-Week High
43.02%
51.44%
Dividend Yield
0%
0%
Shareholder Yield
-9.64%
-1.33%
1-Year Price Total Return
-51.87%
-20.32%
Beta (5-Year)
--
0.520
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$5.13
200-day SMA
Sell
Level
$6.26
Bollinger Bands (100)
Buy
Level
4.93 - 5.87
Chaikin Money Flow
Sell
Level
-1.5M
20-day SMA
Buy
Level
$4.88
Relative Strength Index (RSI14)
Buy
Level
58.83
ADX Line
Buy
Level
12.83
Williams %R
Sell
Level
-2.8846
50-day SMA
Buy
Level
$5.34
MACD (12, 26)
Sell
Level
-0.01
25-day Aroon Oscillator
Sell
Level
-44
On Balance Volume
Sell
Level
-1M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-7.4782)
Sell
CA Score
(Annual)
Level (-2.1021)
Buy
Beneish M-Score
(Annual)
Level (-4.0146)
Sell
Momentum Score
Level (2)
Sell
Ohlson Score
Level (4.5259)
Sell
Piotroski F Score
(Annual)
Level (3)
Sell
Quality Ratio Score
Level (3)
Buy
Fundamental Score
Level (4)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Bolt Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer. Its pipeline includes BDC-1001, a HER2-targeting Boltbody Immune-Stimulating Antibody Conjugate (ISAC), BDC-3042, a myeloid-modulating antibody, and multiple Boltbody ISAC collaboration programs. The company was founded by Edgar G. Engleman on January 22, 2015 and is headquartered in Redwood City, CA.
Stock Forecast FAQ
In the current month, BOLT has received 2 Buy ratings 3 Hold ratings, and 0 Sell ratings. The BOLT average analyst price target in the past 3 months is $22.00.
-
Where Will Bolt Biotherapeutics, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Bolt Biotherapeutics, Inc. share price will rise to $22.00 per share over the next 12 months.
-
What Do Analysts Say About Bolt Biotherapeutics, Inc.?
Analysts are divided on their view about Bolt Biotherapeutics, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Bolt Biotherapeutics, Inc. is a Sell and believe this share price will drop from its current level to $1.00.
-
What Is Bolt Biotherapeutics, Inc.'s Price Target?
The price target for Bolt Biotherapeutics, Inc. over the next 1-year time period is forecast to be $22.00 according to 5 Wall Street analysts, 2 of them rate the stock a Buy, 0 rate the stock a Sell, and 3 analysts rate the stock a Hold.
-
Is BOLT A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Bolt Biotherapeutics, Inc. is a Hold. 3 of 5 analysts rate the stock a Hold at this time.
-
How Can I Buy Shares Of BOLT?
You can purchase shares of Bolt Biotherapeutics, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Bolt Biotherapeutics, Inc. shares.
-
What Is The Bolt Biotherapeutics, Inc. Share Price Today?
Bolt Biotherapeutics, Inc. was last trading at $5.31 per share. This represents the most recent stock quote for Bolt Biotherapeutics, Inc.. Yesterday, Bolt Biotherapeutics, Inc. closed at $5.42 per share.
-
How To Buy Bolt Biotherapeutics, Inc. Stock Online?
In order to purchase Bolt Biotherapeutics, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get BOLT Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
BOLT
Sector
P/E ratio
--
23.75x
PEG ratio
0.00x
-0.01x
P/B ratio
0.32x
1.83x
Price / LTM sales
11.50x
1.60x
Growth Metrics
BOLT
Sector
Revenue growth
90.1%
4.85%
Earnings growth
-837.98%
11.11%
Revenue (5-year growth)
104.5%
6.45%
Earnings forecast
-$5.40
-$0.20
Profitability
BOLT
Sector
Profitability FY 2024
$5.5M
$3.6M
Return on invested capital
-58.81%
-30.98%
Return on assets
-49.02%
-27.62%
Return on equity
-86.41%
-36.69%
Earnings Date
Last Earnings Date
Aug
14
Next Earnings Date
Dec
8
Estimated Next Earnings Date
Mar
9
Balance Sheet
BOLT
Sector
Total cash
$32.7M
$27.2M
Short term investments
$40.1M
$25.7M
Total assets
$99.6M
$79.7M
Long term debt
$20.9M
$4.1M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will Robinhood Win AI Investing?
Recently, online brokerage Robinhood (NASDAQ:HOOD) has been focused on introducing…
Is Amazon an AI Stock?
With the market starting to look skittish on pure-play AI…
Stock Ideas
Buy
52
Is NVDA Stock a Buy?
Market Cap: $4.4T
P/E Ratio: 62x
Buy
56
Is AAPL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 37x
Buy
81
Is GOOG Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 40x
Alerts
Sell
50
TGL alert for Dec 8
Treasure Global, Inc. [TGL] is up 31.68% over the past day.
Buy
56
SMX alert for Dec 8
SMX (Security Matters) Plc [SMX] is down 45.78% over the past day.
Buy
62
PRAX alert for Dec 8
Praxis Precision Medicines, Inc. [PRAX] is up 8.15% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
